Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia

被引：15

作者：

Jose Gonzalez-Lopez, Tomas ^{[1
]}

Sanchez-Gonzalez, Blanca ^{[2
]}

Pascual, Cristina ^{[3
]}

Arefi, Maryam ^{[4
]}

de Cabo, Erik ^{[5
]}

Alonso, Arancha ^{[6
]}

Martin-Salces, Monica ^{[7
]}

Jimenez-Barcenas, Reyes ^{[8
]}

Calbacho, Maria ^{[9
]}

Galan, Pilar ^{[10
]}

Barez, Abelardo ^{[11
]}

Ramon Gonzalez-Porras, Jose ^{[12
]}

机构：

[1] Hosp Univ Burgos, Serv Hematol, Burgos, Spain

[2] Hosp del Mar, Serv Hematol, Barcelona, Spain

[3] Hosp Gregorio Maranon, Serv Hematol, Madrid, Spain

[4] Hosp Clin Univ Valladolid, Serv Hematol, Valladolid, Spain

[5] Hosp Bierzo, Serv Hematol, Leon, Spain

[6] Hosp Univ Quiron, Serv Hematol, Madrid, Spain

[7] Hosp Univ La Paz IDIPaz, Serv Hematol, Madrid, Spain

[8] Hosp Univ Virgen del Rocio, Serv Hematol, Seville, Spain

[9] Hosp Ramon & Cajal, Serv Hematol, E-28034 Madrid, Spain

[10] Hosp Mateu Orfilia Mahon, Serv Hematol, Mahon, Balearic Island, Spain

[11] Complejo Asistencial Avila, Serv Hematol, Avila, Spain

[12] IBSAL Hosp Univ Salamanca, Serv Hematol, Salamanca 37007, Spain

来源：

PLATELETS | 2015年 / 26卷 / 01期

关键词：

Eltrombopag; immune thrombocytopenia; sustained response;

D O I：

10.3109/09537104.2013.870987

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Eltrombopag is effective and safe in chronic immune thrombocytopenia (ITP) patients not responding to previous therapy. However, when eltrombopag is discontinued, platelet counts usually return to baseline within 2 weeks. Here, we describe the clinical characteristics of the, to the best of our knowledge, largest case series of patients with ITP, who presented sustained responses after discontinuing eltrombopag (n = 12). The median time from diagnosis to eltrombopag initiation was 24 months (range, 1-480). The median number of prior therapies was 5 (range, 1-7), and the median duration of eltrombopag treatment was 5 months (range, 1-13). Three patients received eltrombopag for only 1 month. The treatment was well-tolerated. The median (range) follow-up of this case series was of 7 months (6-20), during which all patients maintained a safe platelet count without the need for anti-ITP treatment. The communication of such cases may support the conduction of new studies to investigate which predictive factors could identify ITP patients with sustained responses after discontinuing eltrombopag without additional therapy. The need of long-term use of eltrombopag should be re-examined.

引用

页码：83 / 86

页数：4

共 12 条

[1] Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents [J].